phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

Summary

PRIMARY OBJECTIVE \- To evaluate the efficacy (according to the International Working Group response criteria for Hodgkin's Lymphomas \[7, 8, 9\]) of daily oral doses of ITF2357 administered to very high-risk Hodgkin's lymphoma patients. SECONDARY OBJECTIVES * To evaluate safety and tolerability of multiple oral doses of ITF2357 * To assess the proportion of patients that, after ITF2357 treatment, can undergo high-dose salvage chemotherapy with either autografting or allografting

Timeline

Start

2007-05

Primary completion

2009-03

Completion

2009-03

Drugs

Indications